LB Pharmaceuticals to Participate in Upcoming March Investor Events
LB Pharmaceuticals (Nasdaq: LBRX) announced management will present at two investor events in March 2026: the Leerink 2026 Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET and the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 2:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LB Pharmaceuticals (Nasdaq: LBRX) announced management will present at two investor events in March 2026: the Leerink 2026 Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET and the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 2:30 p.m. ET.
A live webcast and archived replay will be available in the Investors > Events section of the company website at https://lbpharma.us/.
Details
News Market Reaction – LBRX
On Mar 5, the first trading day after this news, LBRX closed 3.48% below the previous close.
Data tracked by StockTitan Argus for the Mar 5 session.
Key Figures
- Leerink conference date
- March 11, 2026
- Leerink 2026 Global Healthcare Conference presentation date
- Leerink conference time
- 1:40 p.m. ET
- Scheduled time for Leerink conference presentation
- Stifel forum date
- March 17, 2026
- Stifel 2026 Virtual CNS Forum presentation date
- Stifel forum time
- 2:30 p.m. ET
- Scheduled time for Stifel CNS forum presentation
Historical Context
-
Options granted to new General Counsel under Nasdaq inducement rules.
-
Announced $100M private placement to fund LB-102 Phase 2 and operations.
-
Initiated Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar I depression.
-
Appointed experienced General Counsel to support CNS-focused strategy.
-
Reported stock option grants to two new senior hires under inducement plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that management will present and participate in the following upcoming investor conferences:
Leerink 2026 Global Healthcare Conference
Date: Wednesday, March 11, 2026
Time: 1:40 p.m. ET
Stifel 2026 Virtual CNS Forum
Date: Tuesday, March 17, 2026
Time: 2:30 p.m. ET
A live webcast of the presentations will be available on the “Investors” section under the “Events” section of the Company’s website at https://lbpharma.us/ where a replay of the webcasts will be archived.
About LB Pharmaceuticals
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Media and Investor Contact
Ellen Rose
erose@lbpharma.us
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.